| Host: | Rabbit |
| Applications: | IHC-P |
| Reactivity: | Human |
| Note: | STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description : | Rabbit monoclonal antibody anti-ALK-p80 (1058-1620aa) is suitable for use in Immunohistochemistry research applications. |
| Clonality : | Monoclonal |
| Clone ID : | ZR305 |
| Conjugation: | Unconjugated |
| Isotype: | IgG |
| Formulation: | Tris-HCI buffer containing stabilizing protein (BSA) and <0.1% ProClin |
| Purification: | Affinity purified |
| Dilution Range: | 1:100-200 |
| Storage Instruction: | Store at 2‐8°C for up to 24 months. Predilute: Ready to use, no reconstitution necessary. Concentrate: Use dilution range and appropriate lab‐standardized diluent. Stability after dilution: 7 days at 24°C, 3 months at 2‐8°C, 6months at ‐20°C. |
| Immunogen Region: | 1058-1620aa |
| Specificity: | Positive control: Anaplastic large cell lymphoma or Lung adenocarcinoma with ALK translocation |
| Immunogen: | Human ALK-1 protein fragment around aa 1058-1620 |
| Background | Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase of the insulin receptor superfamily. ALK-1 is typically expressed at low levels in regions of the developing central and peripheral nervous system. ALK-1 may be activated in cancer through multiple mechanisms. The most common mechanism is through the formation of a fusion protein from chromosomal translocations, as in the case of anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumors. ALK-1 may also be amplified through mutation, as in neuroblastomas. Various solid tumors, such as non-small cell lung carcinoma (NSCLC) and brain cancers were also found to aberrantly express ALK-1. ALK-1 staining is present within both the nucleus and cytoplasm and is positive in about 60% of ALCL. ALK-1 protein expression by tumor cells is an independent prognostic factor that predicts a favorable outcome. |
Information sourced from Uniprot.org